Filtered By:
Specialty: Cardiology
Therapy: Statin Therapy
This page shows you your search results in order of date. This is page number 14.
Order by Relevance | Date
Total 1444 results found since Jan 2013.
Lipid-Modifying Therapies and Stroke Prevention
Curr Neurol Neurosci Rep. 2022 May 13. doi: 10.1007/s11910-022-01197-4. Online ahead of print.ABSTRACTPURPOSE OF REVIEW: We reviewed lipid-modifying therapies and the risk of stroke and other cerebrovascular outcomes, with a focus on newer therapies.RECENT FINDINGS: Statins and ezetimibe reduce ischemic stroke risk without increasing hemorrhagic stroke risk. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors similarly reduce ischemic stroke risk in statin-treated patients with atherosclerosis without increasing hemorrhagic stroke, even with very low achieved low-density lipoprotein cholesterol levels. Icosape...
Source: Atherosclerosis - May 13, 2022 Category: Cardiology Authors: Daniel G Hackam Robert A Hegele Source Type: research
Orphan GPR146: an alternative therapeutic pathway to achieve cholesterol homeostasis?
Trends Endocrinol Metab. 2022 May 9:S1043-2760(22)00065-0. doi: 10.1016/j.tem.2022.04.008. Online ahead of print.ABSTRACTAtherosclerosis predisposes to myriad cardiovascular complications, including myocardial infarction and stroke. Statins have revolutionised cholesterol management but they do not work for all patients, particularly those with familial hypercholesterolaemia (FH). Genome-wide association studies have linked SNPs at orphan G protein-coupled receptor 146 (GPR146) to human atherosclerosis but how GPR146 influences serum cholesterol homeostasis was only recently described. Gpr146 deletion in mice reduces serum...
Source: Atherosclerosis - May 13, 2022 Category: Cardiology Authors: Brendan P Wilkins Angela M Finch Yan Wang Nicola J Smith Source Type: research
Conservative treatment of peripheral arterial disease
Internist (Berl). 2022 May 9. doi: 10.1007/s00108-022-01342-8. Online ahead of print.ABSTRACTPatients with peripheral arterial disease (PAD) often have polyvascular atherosclerosis and are at increased risk of major adverse cardiovascular events (MACE), such as cardiovascular death, myocardial infarction or stroke, and major adverse limb events (MALE), such as amputation and acute limb ischemia. Therefore, the aim of conservative treatment is the reduction of MACE and MALE. In patients with intermittent claudication, the aim is also to extend walking distance. Management of risk factors includes smoking cessation, statin t...
Source: Atherosclerosis - May 9, 2022 Category: Cardiology Authors: Christine Espinola-Klein Gerhard Wei ßer Source Type: research
Polycystic ovary syndrome: a "risk-enhancing" factor for cardiovascular disease
Fertil Steril. 2022 May;117(5):924-935. doi: 10.1016/j.fertnstert.2022.03.009.ABSTRACTPolycystic ovary syndrome (PCOS) is the most common endocrine disorder among women of reproductive age and is hallmarked by hyperandrogenism, oligo-ovulation, and polycystic ovarian morphology. Polycystic ovary syndrome, particularly the hyperandrogenism phenotype, is associated with several cardiometabolic abnormalities, including obesity, dyslipidemia, elevated blood pressure, and prediabetes or type 2 diabetes. Many, but not all, studies have suggested that PCOS is associated with increased risk of cardiovascular disease (CVD), includi...
Source: Atherosclerosis - May 5, 2022 Category: Cardiology Authors: Carolyn Guan Salman Zahid Anum S Minhas Pamela Ouyang Arthur Vaught Valerie L Baker Erin D Michos Source Type: research
Potential role for pentoxifylline as an anti-inflammatory drug for patients with acute coronary syndrome
Exp Ther Med. 2022 Jun;23(6):378. doi: 10.3892/etm.2022.11305. Epub 2022 Apr 8.ABSTRACTThe link between inflammation and acute coronary syndrome (ACS) remains to be sufficiently elucidated. It has been previously suggested that there is an inflammatory process associated with ACS. Pentoxifylline, a methylxanthine derivate, is known to delay the progression of atherosclerosis and reduce the risk of vascular events, especially by modulating the systemic inflammatory response. The present study is a single-blind, randomized, prospective study of pentoxifylline 400 mg three times a day (TID) added to standard therapy vs. stand...
Source: Atherosclerosis - May 2, 2022 Category: Cardiology Authors: Daniel Miron Brie Cristian Mornos Diduta Alina Brie Constantin Tudor Luca Lucian Petrescu Madalina Boruga Source Type: research
PCSK9 inhibition in patients with acute stroke and symptomatic intracranial atherosclerosis: protocol for a prospective, randomised, open-label, blinded end-point trial with vessel-wall MR imaging
BMJ Open. 2022 Apr 29;12(4):e060068. doi: 10.1136/bmjopen-2021-060068.ABSTRACTINTRODUCTION: Dual antiplatelet therapy and high-intensity statins are the mainstay treatment in patients with acute stage, symptomatic intracranial atherosclerotic stenosis (ICAS). Alirocumab is a monoclonal antibody that can inhibit proprotein convertase subtilisin-kexin type 9 and effectively lower low-density lipoprotein cholesterol levels with less side effects than statins. We hypothesise that alirocumab treatment in addition to statin therapy could stabilise intracranial plaque and reduce arterial stenosis.METHODS AND ANALYSIS: In this pro...
Source: Atherosclerosis - April 29, 2022 Category: Cardiology Authors: Yen-Chu Huang Chia-Hao Chang Yuan-Hsiung Tsai Hsu-Huei Weng Leng-Chieh Lin Jiann-Der Lee Source Type: research
Cardiovascular Risk and Treatment Outcomes in Severe Hypercholesterolemia: A Nationwide Cohort Study
Conclusions Using large Korean cohort data, our study proved incrementally elevated cardiovascular risk and clinical benefit associated with LDL-C<100 mg/dL in individuals with severe hypercholesterolemia. These results support aggressive lipid lowering and provide evidence for the LDL-C target in this population.PMID:35470675 | DOI:10.1161/JAHA.121.024379
Source: Atherosclerosis - April 26, 2022 Category: Cardiology Authors: Chan Joo Lee Sanghyun Park Kyungdo Han Sang-Hak Lee Source Type: research
Nontraditional Risk Factors for Residual Recurrence Risk in Patients with Ischemic Stroke of Different Etiologies
CONCLUSIONS: LAA and SAO subtypes own the specific nontraditional risk factors while inflammation is a common risk factor for residual recurrence risk of both.PMID:35390802 | DOI:10.1159/000523919
Source: Atherosclerosis - April 7, 2022 Category: Cardiology Authors: Jie Xu Jinglin Mo Xing Zhang Zimo Chen Yuesong Pan Hongyi Yan Xia Meng Yongjun Wang Source Type: research
Correspondence on 'Omega-3 supplementation and cardiovascular disease: formulation-based systematic review and meta-analysis with trial sequential analysis' by Rizos et al
In their review and meta-analysis, Rizos et al1 reported that omega-3 supplementation at low and higher dosages showed no or weak associations with cardiovascular disease (CVD) outcomes, respectively. More recent reviews also showed protective activity of omega-3 against CVD outcomes. For instance, omega-3 (2–4 g/day) in patients with high or very high triglyceride (TG) levels decreases significantly high-sensitivity C reactive protein (hsCRP), lipoprotein-associated phospholipase A2 (Lp-PLA2), and oxidised low density lipoprotein (LDL)-cholesterol (oxLDL) levels, and the reduction of hsCRP is enhanced when co-admini...
Source: Heart - March 25, 2022 Category: Cardiology Authors: Kountouras, J., Doulberis, M., Kazakos, E., Tzika, S. K., Vardaka, E., Liatsos, C., Papaefthymiou, A. Tags: Correspondence Source Type: research
Medical Management Best for Atherosclerotic Stroke: AAN Medical Management Best for Atherosclerotic Stroke: AAN
An advisory from the American Academy of Neurology on preventing recurrent stroke in symptomatic intracranial atherosclerosis recommends antiplatelets and statins but advises against stenting.Medscape Medical News
Source: Medscape Cardiology Headlines - March 24, 2022 Category: Cardiology Tags: Cardiology News Source Type: news
High Triglycerides Up CV Risk After Atherothrombotic Stroke High Triglycerides Up CV Risk After Atherothrombotic Stroke
A new study shows higher risk for further cardiovascular events and strokes in patients with a recent stroke of atherothrombotic origin and raised triglyceride levels, even accounting for statin use.Medscape Medical News
Source: Medscape Cardiology Headlines - March 23, 2022 Category: Cardiology Tags: Cardiology News Source Type: news
Comparing pharmacotherapy in MINOCA versus medically managed obstructive acute coronary syndrome
This study uniquely compares the management and outcomes of MINOCA patients with a medically managed obstructive ACS (M-ACS) population. We retrospectively analysed registry data for consecutive patients admitted to the Gold Coast University Hospital with ACS requiring coronary angiography and identified patients with MINOCA and M-ACS. Baseline characteristics, pharmacological therapy and in-hospital outcomes were compared. In hospital outcomes were composite NACE, heart failure, stroke and major bleeding. Multivariate regression analysis was also performed to identify independent predictors of MINOCA. Multivariate regress...
Source: Heart and Vessels - March 23, 2022 Category: Cardiology Source Type: research
